Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized double-blind placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent, persistent and/or metastasizing) medullary thyroid carcinoma [Randomisierte, doppelblinde, Placebo-kontrollierte Phase II-Studie zur Bewertung von Wirksamkeit und Sicherheit einer Behandlung mit Sorafenib bei Patienten mit medullärem Schilddrüsenkarzinom]

Next Previous
X
Search
Trial Profile

Randomized double-blind placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent, persistent and/or metastasizing) medullary thyroid carcinoma [Randomisierte, doppelblinde, Placebo-kontrollierte Phase II-Studie zur Bewertung von Wirksamkeit und Sicherheit einer Behandlung mit Sorafenib bei Patienten mit medullärem Schilddrüsenkarzinom]

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Thyroid cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms SUMMIT

    • Most Recent Events

    • 16 May 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 28 Nov 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01736878).
    • 28 Nov 2012 Planned End Date changed from 11 Jan 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top